Clinical trial · no report yet · Phase 3
NCT03713593
Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
- NCT03713593 ↗
- Completed
- Merck Sharp & Dohme LLC
- 58 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 30 | |
| Podcasts | 16 | |
| YouTube | 12 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants With Advanced Hepatocellular Carcinoma (LEAP-002)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- lenvatinib; pembrolizumab; saline placebo
- Arms
- lenvatinib plus pembrolizumab · Experimental
- lenvatinib plus placebo · Active comparator
- Enrollment
- 794
- Primary outcomes
- Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
- Overall Survival (OS)
- Sponsor
- Merck Sharp & Dohme LLC with Eisai Inc.
- Start
- Dec 31, 2018
- Primary completion
- Jun 21, 2022
- Results posted
- Yes
- Registry record
- NCT03713593 · updated Feb 5, 2026
Publications
linked from the registry- Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2. PubMed 38039993